Capricor plans for deramiocel resubmission after FDA rejection

Capricor plans for deramiocel resubmission after FDA rejection

Capricor Therapeutics will resubmit its application for U.S. Food and Drug Administration (FDA) approval of its cell therapy deramiocel to treat Duchenne muscular dystrophy (DMD)-related heart disease, following the agency’s decision to not accept the original filing. According to a company press release, the FDA issued a…

Finding solace: Why I need July’s slower pace

July is my favorite month. Many people who know me might be surprised by that, as they’re aware that I’m a Christmas enthusiast who loves to decorate, making my house look like the North Pole for nearly eight weeks every winter. I spend the other 10 months of the year…

Households caring for DMD patients face high costs: US survey

Households incur substantial costs to accommodate people with Duchenne muscular dystrophy (DMD), according to a survey of patient caregivers in the U.S. Costs, such as those for purchasing and/or modifying an accessible vehicle, relocating to or building an accessible home, modifying home entrances, and buying medical equipment, were particularly…

Giving thanks that my 3 sons with DMD have one another

Summer vacation in the Midwest typically begins in mid-May, and kids return to school by mid-August. Here in Nebraska, that puts us halfway through summer break already. Like most moms, I’m feeling a mix of emotions: grief as I anticipate the end of these few precious weeks home with my…

Disease progression reflected by blood protein signature: Study

Researchers identified a unique protein signature in the bloodstreams of adults with Becker muscular dystrophy (BMD) and limb-girdle muscular dystrophy (LGMD) that significantly differs from healthy individuals after exercise. “We propose that a subset of circulating proteins may be more indicative of disease progression and/or therapeutic efficacy than…